The new technology will enable biologics that are given as aqueous injections to be reformulated into a biocompatible, non-aqueous suspensions.
The suspensions can be directly injected without reconstitution saving time during medical emergencies.
Intracutaneous Injection has applications in the development of reformulated drug products.
The first application of the technology will be the development of an injectable form of diazepam for the emergency treatment of seizures, the company said.
The patent will allow for the development of products across drug classes including peptides, proteins, and small molecules.
Xeris chief scientific officer and co-founder Steve Prestrelski said that the patent will support immediate and sustained release formulations.